title: The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
abstract: BACKGROUND
  Hypomethylating agents (HMAs) are the standard of care for patients with higher-risk myelodysplastic syndromes (MDS), but patients who relapse or are refractory have a poor prognosis with an estimated survival of 4-6 months. Rigosertib, a Ras mimetic that inhibits the phophoinositide 3-kinase and polo-like kinase pathways, has been tested in patients with higher-risk MDS following treatment with HMAs, where there are no approved second-line therapies.
  
  
  METHODS
  This review will provide an overview of rigosertib, including safety and efficacy demonstrated in clinical trials. Expert commentary: There is an urgent need for new treatment options for patients who have failed or progressed on HMAs. Rigosertib is currently undergoing testing as a single agent in certain subsets of higher-risk MDS patients as well as in combination with azacitidine, where preliminary data show efficacy in patients with de novo MDS as well as HMA failures.
authors.affiliation: a Tisch Cancer Institute, Division of Hematology/Oncology , Icahn School of Medicine at Mount Sinai , New York , NY , USA.
authors.forename: Shyamala C
authors.initials: SC
authors.lastname: Navada
authors.affiliation: a Tisch Cancer Institute, Division of Hematology/Oncology , Icahn School of Medicine at Mount Sinai , New York , NY , USA.
authors.forename: Lewis R
authors.initials: LR
authors.lastname: Silverman
mesh_terms: D001374:Azacitidine / Q000008:administration & dosage* / Q000627:therapeutic use; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005998:Glycine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000503:physiopathology; D011379:Prognosis; D013450:Sulfones / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D013450:Sulfones; C507134:ON 01910; D001374:Azacitidine; D005998:Glycine
keywords: DNA methyltransferase inhibitors; Myelodysplastic syndromes; ON 0910.Na; Ras-binding domain; hypomethylating agents; phosphatidylinositol 3-kinase; polo-like kinase; rigosertib